Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.36 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.36 |
| ▸ | KLK1 | P06870 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10020940 | 0.87 | MAOB (0.39) | FPR2SCN9AABCC9ABCC8KCNJ11 | |
| SCHEMBL24965982 | 0.87 | EPHX2 (0.41) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL29563554 | 0.87 | KDM4E (0.40) | ABCC9ABCC8KCNJ11KCNJ8CDK1 | |
| SCHEMBL17658331 | 0.87 | KDM4E (0.40) | ABCC9ABCC8KCNJ11KCNJ8CDK1 | |
| SCHEMBL18307303 | 0.87 | DGAT1 (0.47) | DGAT1FPR2SCN9APARP10PARP14 | |
| SCHEMBL191113 | 0.85 | DGAT1 (0.46) | DGAT1PARP10PARP14PARP15ABCC9 | |
| SCHEMBL12321278 | 0.85 | NPC1 (0.39) | FPR2SCN9AABCC9ABCC8KCNJ11 | |
| SCHEMBL29644326 | 0.84 | GAA (0.44) | ABCC9ABCC8KCNJ11KCNJ8KCNH2 | |
| SCHEMBL2411518 | 0.84 | GAA (0.44) | ABCC9ABCC8KCNJ11KCNJ8KCNH2 | |
| SCHEMBL582706 | 0.83 | POLB (0.44) | ABCC9ABCC8KCNJ11KCNJ8KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643931-B2 | Process for preparing enzalutamide | SCINOPHARM TAIWAN, LTD. (TW) | 2017-05-09 | — | — | US | disclosed |
| WO-2016200338-A1 | A NOVEL PROCESS FOR PREPARING ENZALUTAMIDE | SCINOPHARM TAIWAN, LTD. (TW) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362381-A1 | NOVEL PROCESS FOR PREPARING ENZALUTAMIDE | SCINOPHARM TAIWAN, LTD. (TW) | 2016-12-15 | — | — | US | disclosed |
| US-9023879-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023879-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2400847-B1 | SPECIFIC DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS INC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2400847-B1 | SPECIFIC DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20130331421-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8524755-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524755-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| CN-102421291-A | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS INC | 2012-04-18 | — | — | CN | disclosed |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2012-02-09 | — | — | US | disclosed |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2012-02-09 | — | — | US | disclosed |
| EP-2400847-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010099238-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099238-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331421-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | BPHL, PARK7, APP | DGAT1 927/4885FPR2 2340/4885SCN9A 2886/4885 |
| US-20160362381-A1 | NOVEL PROCESS FOR PREPARING ENZALUTAMIDE | AR, KLK5, KLK3 | DGAT1 1817/4885FPR2 4517/4885SCN9A 3811/4885 |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | BPHL, PARK7, APP | DGAT1 927/4885FPR2 2340/4885SCN9A 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.